Education · Tier 4
· Last Reviewed May 12, 2026· PSI Editorial Board· IndependentWhat Bloodwork Is Required for Tissue Repair Peptides?
The honest reference for compounded tissue repair peptide baseline bloodwork across BPC-157 and TB-500 therapy under AMA Code of Medical Ethics 1.1.5 framework and FDA Compounding Quality Act of 2013.
Compounded tissue repair peptide therapy with BPC-157 and TB-500 requires baseline CMP and CBC.
The framework operates under AMA Code of Medical Ethics 1.1.5.
The evidence base is primarily preclinical with limited human trial data.
Physician pharmacy verification is required for 503A or 503B pathways.
Quick Answer
Compounded tissue repair peptide therapy with BPC-157 and TB-500 requires baseline safety markers plus AMA Code 1.1.5 documentation. The framework anchors in the FDA Compounding Quality Act of 2013.
For BPC-157 (compounded gastric pentadecapeptide derivative), baseline includes comprehensive metabolic panel and complete blood count. The 15 amino acid sequence is derived from gastric juice protein. Evidence base is primarily preclinical with limited human trial data.
For TB-500 (compounded thymosin beta-4 fragment), baseline includes the same foundational safety markers. The compound is a synthetic 17 amino acid fragment of thymosin beta-4. Evidence base is primarily preclinical with limited human trial data.
AMA Code of Medical Ethics 1.1.5 framework applies to all compounded peptide prescribing. The documentation includes risk-benefit assessment for the specific patient context. The documentation also includes alternatives considered including FDA-approved options where applicable.
Physician verification of 503A state pharmacy or 503B FDA-registered outsourcing facility is required. Verification includes PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party purity and potency testing practices.
Monitoring follows a four-stage cadence. The stages are baseline at week 0, early follow-up at week 4 to 8, and stabilization at month 3. The maintenance stage is at month 6 with annual continuation. See Bloodwork Before Peptide Therapy for the full framework. For prescription pathway context, see Compounded vs FDA-Approved.
The baseline framework spans foundational safety markers plus AMA Code 1.1.5 documentation. The comprehensive metabolic panel covers kidney function via creatinine, BUN, and eGFR. The panel covers liver function via AST, ALT, alkaline phosphatase, and total bilirubin. Electrolyte balance is also captured. The complete blood count establishes hematologic baseline. The CBC also screens for occult disease. AMA Code 1.1.5 documentation includes risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding. The compounded preparation operates outside FDA pre-market approval per the FDA Compounding Quality Act of 2013.
TISSUE REPAIR PEPTIDE BLOODWORK
At a Glance: Bloodwork for Tissue Repair Peptides
| Marker / Test | Subtitle | Animal Evidence | Human Evidence | Clinical Rationale |
|---|---|---|---|---|
| Comprehensive metabolic panel (CMP) | Kidney, liver, and electrolyte baseline for compounded peptide safety | — | Moderate | Foundational safety baseline for any compounded peptide therapy. Covers creatinine, BUN, eGFR, AST, ALT, ALP, bilirubin, electrolytes |
| Complete blood count (CBC) | Hematologic baseline and occult disease screening | — | Moderate | Foundational safety baseline. Captures white blood cell, red blood cell, hemoglobin, hematocrit, and platelet count |
| AMA Code of Medical Ethics 1.1.5 documentation | Informed consent for off-label and compounded prescribing | — | Strong | Required for all compounded peptide prescribing. Documents risk-benefit, alternatives considered, monitoring, patient understanding |
| 503A or 503B pharmacy verification | Pharmacy quality assurance documentation | — | Strong | Physician verification of state license or FDA registration, PCAB accreditation, USP compliance, third-party testing |
| Inflammation markers (CRP, ESR) as indicated | Inflammation baseline for tissue repair indication context | — | Limited | May apply for inflammatory tissue repair indications. Decision based on clinical context per AMA Code 1.1.5 |
| Hormone panel as indicated | Hormonal context for tissue healing where clinically relevant | — | Limited | Testosterone, IGF-1, thyroid function may apply per clinical context. Decision per specialty coordination |
| Lipid panel baseline | Cardiovascular and metabolic context baseline | — | Limited | General cardiovascular baseline. Not specifically required for tissue repair indications but supports overall framework |
| Four-stage monitoring cadence | Baseline, early follow-up, stabilization, maintenance | — | Strong | Baseline week 0, early follow-up week 4-8, stabilization month 3, maintenance month 6 plus annual continuation |
Six Things You Need to Know About Tissue Repair Peptide Bloodwork
This page covers compounded tissue repair peptide baseline bloodwork in detail. The framework spans the compounded BPC-157 and TB-500 class. Section one covers the foundational safety markers (CMP and CBC). Section two covers AMA Code 1.1.5 informed consent documentation. Section three covers 503A and 503B pharmacy verification. Section four covers the four-stage monitoring cadence under compounded pathway constraints.
Compounded Tissue Repair Peptides Operate Outside FDA Pre-Market Approval
BPC-157 and TB-500 are compounded peptides that operate outside FDA pre-market approval per the FDA Compounding Quality Act of 2013. The compounded preparations are not FDA-approved drugs.
The FDA Compounding Quality Act of 2013 established two compounding pathways. The 503A pathway covers individual prescription compounding through state pharmacy board licensed compounding pharmacies. The 503B pathway covers office-administered compounded preparations through FDA-registered outsourcing facilities. Neither pathway requires FDA pre-market approval of the compounded preparation itself. BPC-157 (gastric pentadecapeptide derivative) and TB-500 (synthetic thymosin beta-4 fragment) are available only through these compounded pathways. The regulatory framework differs substantially from FDA-approved drugs like Wegovy or Forteo which undergo Phase 1-3 clinical trial evaluation and FDA New Drug Application approval. Compounded tissue repair peptide prescribing operates under AMA Code of Medical Ethics 1.1.5 framework. The framework requires documented risk-benefit assessment, alternatives considered including FDA-approved options where applicable, monitoring requirements, and patient understanding. Specialty coordination strengthens the framework.
CMP Establishes Kidney and Liver Function Baseline for Compounded Therapy
Comprehensive metabolic panel (CMP) is the foundational safety baseline for any compounded peptide therapy. The panel covers kidney function, liver function, and electrolyte balance.
The comprehensive metabolic panel includes 14 standard analytes. Kidney function markers are creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). Liver function markers are aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin. Electrolyte markers are sodium, potassium, chloride, carbon dioxide, and glucose. Calcium and total protein complete the panel. For compounded BPC-157 and TB-500 therapy, the CMP establishes baseline safety status. The framework supports detection of pre-existing kidney or liver disease before therapy initiation. The framework also supports ongoing monitoring across the therapy course given the limited human safety data for these compounded preparations. Monitoring intervals follow the four-stage cadence with CMP re-check at month 3 stabilization and month 6 maintenance stages. AMA Code 1.1.5 framework requires documented clinical interpretation of baseline findings.
CBC Establishes Hematologic Baseline and Screens for Occult Disease
Complete blood count (CBC) is the second foundational safety baseline for compounded peptide therapy. The panel establishes hematologic baseline and screens for occult disease before therapy initiation.
The complete blood count includes white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), and platelet count. CBC with differential adds neutrophil, lymphocyte, monocyte, eosinophil, and basophil percentages. For compounded BPC-157 and TB-500 therapy, the CBC establishes hematologic baseline. The framework supports detection of pre-existing anemia, thrombocytopenia, leukopenia, or hematologic malignancy before therapy initiation. The framework also captures ongoing monitoring across the therapy course. For tissue repair indications, baseline CBC supports detection of inflammation patterns that may inform clinical context. Monitoring intervals follow the four-stage cadence with CBC re-check at month 3 stabilization and month 6 maintenance stages. Specialty coordination with hematology applies when baseline findings suggest hematologic pathology.
AMA Code 1.1.5 Documentation Is Mandatory for All Compounded Peptide Prescribing
AMA Code of Medical Ethics 1.1.5 documentation is mandatory for all compounded peptide prescribing including BPC-157 and TB-500. The documentation includes risk-benefit assessment, alternatives considered, monitoring requirements, and patient understanding.
AMA Code of Medical Ethics 1.1.5 governs off-label and investigational use of pharmaceuticals. AMA Code 2.1.1 establishes the broader informed consent framework. For compounded BPC-157 and TB-500 prescribing, the documentation must include four elements. First is the risk-benefit assessment for the specific patient context. The assessment incorporates the limited human evidence base, the preclinical mechanism of action, the tissue repair indication, and the patient's clinical situation. Second is alternatives considered. For tissue repair indications, FDA-approved alternatives may include physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma therapy, or surgical intervention depending on the specific condition. Third is monitoring requirements including baseline bloodwork, ongoing safety surveillance, and adverse event reporting protocols. Fourth is patient understanding documented through informed consent acknowledgment. Patients can request copies of the AMA Code 1.1.5 documentation. The framework supports patient autonomy and shared decision-making while protecting both patient and physician within the validated clinical practice foundation.
503A or 503B Pharmacy Verification Is Required for Compounded Pathways
Physician verification of 503A state pharmacy or 503B FDA-registered outsourcing facility is required for compounded BPC-157 and TB-500 prescribing. Verification includes PCAB, USP, and third-party testing practices.
The 503A pharmacy pathway covers individual prescription compounding through state pharmacy board licensed compounding pharmacies. The state license is verified through the state pharmacy board portal. The 503B pathway covers office-administered compounded preparations through FDA-registered outsourcing facilities. The FDA registration is verified through the FDA Drug Establishment Registration database. Pharmacy Compounding Accreditation Board (PCAB) accreditation provides additional quality assurance. PCAB accreditation status is verified through the PCAB website. USP Chapter 797 sterile compounding compliance addresses sterile preparation protocols including aseptic technique, environmental monitoring, and beyond-use dating. USP Chapter 800 hazardous drug handling compliance addresses worker safety and patient exposure protocols. Third-party purity and potency testing supports compounded preparation quality. The testing typically includes USP 71 sterility testing, USP 85 bacterial endotoxin testing, and HPLC potency analysis. Patients should request the specific pharmacy name and verification documentation. The verification documentation supports the AMA Code 1.1.5 informed consent framework.
Four-Stage Monitoring Cadence Captures Compounded Peptide Safety
Monitoring across compounded tissue repair peptide therapy follows a four-stage cadence: baseline at week 0, early follow-up at week 4 to 8, stabilization at month 3, and maintenance at month 6 with annual continuation.
Stage 1 baseline at week 0 establishes the foundational panel: CMP for kidney, liver, and electrolyte baseline plus CBC for hematologic baseline. AMA Code 1.1.5 documentation is completed at baseline. Pharmacy verification documentation is established at baseline. Stage 2 early follow-up at week 4-8 captures early therapy tolerability, side effect emergence, and tissue repair clinical response assessment. CMP and CBC re-check may apply based on baseline findings. Stage 3 stabilization at month 3 captures steady-state response: full CMP and CBC re-check, ongoing tolerability, and clinical response assessment for the tissue repair indication. Stage 4 maintenance at month 6 with annual continuation thereafter applies the full panel re-check. Given the limited human evidence base for BPC-157 and TB-500, conservative monitoring intervals strengthen the safety framework. Adverse event reporting through FDA MedWatch applies for serious events. Specialty coordination strengthens the framework. The PSI physician directory provides verified physicians ordering comprehensive baseline bloodwork for compounded peptide pathways.
Lab Panels by Context
Compounded Tissue Repair Peptide Foundational Baseline Panel
Compounded tissue repair peptide · applies to: BPC-157 (compounded), TB-500 / thymosin beta-4 fragment (compounded)
Compounded tissue repair peptide therapy requires foundational safety baseline through CMP and CBC. The framework operates under AMA Code of Medical Ethics 1.1.5 given the compounded preparations operate outside FDA pre-market approval per FDA Compounding Quality Act of 2013.
Context: 503A or 503B compounded preparations. No FDA-approved product. AMA Code 1.1.5 informed consent documentation required. Specialty coordination strengthens decisions.
| Test | Why ordered | Monitoring |
|---|---|---|
| Comprehensive metabolic panel (CMP) | Foundational safety baseline covering kidney function (creatinine, BUN, eGFR), liver function (AST, ALT, ALP, total bilirubin), and electrolyte balance for any compounded peptide therapy. | baseline, month 3, month 6, annual |
| Complete blood count (CBC) | Hematologic baseline including WBC, RBC, hemoglobin, hematocrit, MCV, platelets. Screens for occult disease and establishes ongoing comparison. | baseline, month 3, month 6, annual |
AMA Code 1.1.5 Documentation Panel
Off-label and compounded prescribing documentation framework · applies to: all compounded peptide prescribing (BPC-157, TB-500, and other compounded indications)
AMA Code of Medical Ethics 1.1.5 documentation is mandatory for compounded peptide prescribing. The documentation requirements support patient autonomy and shared decision-making within validated clinical practice framework.
Context: Mandatory documentation framework. Not a laboratory test but required clinical workflow element captured in medical record. Patients can request copies.
| Test | Why ordered | Monitoring |
|---|---|---|
| Risk-benefit assessment for specific patient context | Documents the clinical rationale for compounded peptide prescribing including indication match, prior interventions tried, patient preferences, and clinical context. Mandatory per AMA Code 1.1.5. | baseline, update at indication change |
| FDA-approved alternatives considered documentation | Documents consideration of FDA-approved alternatives before compounded prescribing. For tissue repair: physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma, surgical intervention as applicable. | baseline |
| Monitoring requirements and adverse event reporting plan | Documents baseline laboratory framework, ongoing monitoring cadence, and adverse event reporting protocols including FDA MedWatch for serious events. | baseline, annual review |
| Patient understanding documentation | Documents patient awareness of evidence base limitations (primarily preclinical), compounded preparation status (outside FDA pre-market approval), and informed consent acknowledgment. | baseline |
503A and 503B Pharmacy Verification Panel
FDA Compounding Quality Act 2013 verification framework · applies to: all compounded peptide prescribing through 503A state pharmacy or 503B FDA-registered outsourcing facility
Physician verification of compounding pharmacy quality assurance is required under the FDA Compounding Quality Act of 2013 framework. Verification supports the AMA Code 1.1.5 informed consent framework and patient confidence in compounded preparation quality.
Context: Mandatory verification framework. Documentation is captured in medical record. Patients can request verification documentation.
| Test | Why ordered | Monitoring |
|---|---|---|
| 503A state license or 503B FDA registration verification | Confirms the compounding pharmacy operates under appropriate regulatory pathway. 503A: state license. 503B: FDA Drug Establishment Registration. | baseline, periodic re-verification |
| PCAB accreditation status verification | Pharmacy Compounding Accreditation Board accreditation provides additional quality assurance verification beyond basic licensure. | baseline, periodic re-verification |
| USP Chapter 797 and 800 compliance verification | USP 797 sterile compounding compliance and USP 800 hazardous drug handling compliance verify sterile preparation protocols and worker safety standards. | baseline |
| Third-party purity and potency testing documentation | USP 71 sterility testing, USP 85 bacterial endotoxin testing, and HPLC potency analysis support compounded preparation quality verification. | baseline, per lot or batch as applicable |
BPC-157 compounded gastric pentadecapeptide derivative baseline
Compounded 15 amino acid sequence derived from gastric juice protein under AMA Code 1.1.5 framework
BPC-157 (body protection compound 157) is a 15 amino acid peptide sequence derived from a protein found in human gastric juice. The compound has been studied primarily in preclinical animal models for tissue repair indications including tendon, ligament, muscle, gastric mucosa, and inflammatory bowel disease contexts. The evidence base for BPC-157 is primarily preclinical with limited human trial data. There is no FDA-approved BPC-157 product. The compound is available only through compounded pathways.
Compounded BPC-157 prescribing operates outside FDA pre-market approval per the FDA Compounding Quality Act of 2013. The 503A pathway applies for individual prescription compounding through state pharmacy board licensed compounding pharmacies. The 503B pathway applies for office-administered compounded preparations through FDA-registered outsourcing facilities. AMA Code of Medical Ethics 1.1.5 framework requires documented risk-benefit assessment for the specific patient context. Alternatives considered for tissue repair indications may include physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma, or surgical intervention depending on the specific condition.
The baseline panel includes comprehensive metabolic panel for kidney and liver function plus complete blood count for hematologic baseline. The framework supports detection of pre-existing pathology before therapy initiation and ongoing safety monitoring across the therapy course. Physician verification of 503A or 503B pharmacy quality assurance applies including PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party purity and potency testing. Specialty coordination strengthens the framework.
TB-500 compounded thymosin beta-4 fragment baseline
Compounded 17 amino acid synthetic fragment of thymosin beta-4 under AMA Code 1.1.5 framework
TB-500 is a synthetic 17 amino acid peptide fragment of thymosin beta-4. The full thymosin beta-4 molecule is a 43 amino acid peptide that occurs naturally in mammalian tissues with high concentrations in platelets, leukocytes, and various other cell types. The TB-500 fragment has been studied primarily in preclinical animal models for tissue repair indications including cardiac, neural, and musculoskeletal contexts. The evidence base for TB-500 is primarily preclinical with limited human trial data. There is no FDA-approved TB-500 product. The compound is available only through compounded pathways.
Compounded TB-500 prescribing operates outside FDA pre-market approval per the FDA Compounding Quality Act of 2013. The regulatory framework is identical to BPC-157: 503A or 503B pathway with AMA Code of Medical Ethics 1.1.5 documentation. Note that TB-500 is on the World Anti-Doping Agency (WADA) prohibited list as a non-specified substance under category S2 peptide hormones, growth factors, and related substances. The WADA prohibition applies to athletes subject to anti-doping testing.
The baseline panel matches BPC-157: comprehensive metabolic panel plus complete blood count. AMA Code 1.1.5 informed consent documentation includes risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding. Physician verification of 503A or 503B pharmacy quality assurance applies. Specialty coordination strengthens the framework. Adverse event reporting through FDA MedWatch applies for serious events.
AMA Code of Medical Ethics 1.1.5 framework for compounded peptide prescribing
Off-label and investigational use of pharmaceuticals framework for compounded BPC-157 and TB-500
AMA Code of Medical Ethics 1.1.5 governs off-label and investigational use of pharmaceuticals. AMA Code 2.1.1 establishes the broader informed consent framework. For compounded peptide prescribing including BPC-157 and TB-500, AMA Code 1.1.5 framework requires four documented elements. First is the risk-benefit assessment for the specific patient context incorporating the limited human evidence base, preclinical mechanism, tissue repair indication, and patient clinical situation.
Second is alternatives considered. For tissue repair indications, FDA-approved alternatives include physical therapy as first-line for most musculoskeletal indications, NSAIDs (ibuprofen, naproxen) for inflammatory pain, corticosteroid injections for joint and tendon indications (with caution for tendon insertions), platelet-rich plasma (PRP) injection therapy, prolotherapy, and surgical intervention for indications meeting surgical criteria. The framework requires documented consideration of these alternatives before compounded peptide prescribing.
Third is monitoring requirements including baseline bloodwork (CMP and CBC), ongoing safety surveillance through the four-stage cadence, and adverse event reporting protocols including FDA MedWatch for serious events. Fourth is patient understanding documented through informed consent acknowledgment. The documentation includes patient awareness of the limited human evidence base, the compounded preparation status outside FDA pre-market approval, and the alternatives considered. Patients can request copies of the documentation.
503A and 503B pharmacy verification for compounded tissue repair peptides
Pharmacy quality assurance documentation framework per FDA Compounding Quality Act of 2013
Pharmacy verification for compounded BPC-157 and TB-500 prescribing operates under the FDA Compounding Quality Act of 2013. The 503A pathway covers individual prescription compounding through state pharmacy board licensed compounding pharmacies. State license verification is through the state pharmacy board portal for the state where the pharmacy operates. The 503B pathway covers office-administered compounded preparations through FDA-registered outsourcing facilities. FDA registration verification is through the FDA Drug Establishment Registration database.
Pharmacy Compounding Accreditation Board (PCAB) accreditation provides additional quality assurance verification. PCAB accreditation status is verified through the PCAB website. USP Chapter 797 sterile compounding compliance addresses sterile preparation protocols. The chapter covers aseptic technique, environmental monitoring, beyond-use dating, and personnel qualification. USP Chapter 800 hazardous drug handling compliance addresses worker safety and patient exposure protocols.
Third-party purity and potency testing supports compounded preparation quality. The testing typically includes USP 71 sterility testing (validating sterile preparation status), USP 85 bacterial endotoxin testing (validating freedom from endotoxin contamination), and HPLC potency analysis (validating active ingredient concentration). Patients should request the specific pharmacy name and verification documentation. The verification documentation supports the AMA Code 1.1.5 informed consent framework and provides patient confidence in compounded preparation quality.
Research Suggests
Direction
Compounded tissue repair peptide therapy baseline bloodwork follows AMA Code of Medical Ethics 1.1.5 framework. The FDA Compounding Quality Act of 2013 governs the pharmacy framework.
The framework spans foundational safety markers (CMP and CBC) plus AMA Code 1.1.5 documentation plus 503A or 503B pharmacy verification. The framework applies across BPC-157 (compounded 15 amino acid gastric pentadecapeptide derivative) and TB-500 (compounded 17 amino acid thymosin beta-4 fragment). Anchored in AMA Code of Medical Ethics 1.1.5 (off-label and investigational use of pharmaceuticals), AMA Code 2.1.1 (informed consent), and FDA Compounding Quality Act of 2013. The evidence base for both compounds is primarily preclinical with limited human trial data.
Strongest evidence
Comprehensive metabolic panel (CMP) and complete blood count (CBC) provide the strongest evidence anchoring for compounded peptide baseline safety assessment.
Comprehensive metabolic panel covers kidney function (creatinine, BUN, eGFR), liver function (AST, ALT, ALP, bilirubin), and electrolyte balance. The panel is the foundational safety baseline for any compounded peptide therapy. Complete blood count covers white blood cell count, red blood cell count, hemoglobin, hematocrit, and platelet count plus differential where indicated. The panel establishes hematologic baseline and screens for occult disease. AMA Code of Medical Ethics 1.1.5 framework provides the strongest regulatory and ethical anchoring for compounded peptide prescribing. The framework requires documented risk-benefit assessment, alternatives considered, monitoring requirements, and patient understanding.
Limitations
The evidence base for BPC-157 and TB-500 efficacy is primarily preclinical with limited human trial data. The compounded preparations operate outside FDA pre-market approval.
BPC-157 and TB-500 have been studied primarily in preclinical animal models for tissue repair indications. There is no FDA-approved product for either compound. The compounded preparations operate outside FDA pre-market approval per the FDA Compounding Quality Act of 2013. Human trial data is limited and the available human studies have been small with short follow-up. Long-term safety data is limited. AMA Code 1.1.5 framework requires documented patient understanding of these evidence base limitations. FDA-approved alternatives for tissue repair indications include physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma, and surgical intervention depending on the specific condition. TB-500 specifically is on the World Anti-Doping Agency prohibited list for athletes subject to anti-doping testing.
Assessment
The framework establishes compounded tissue repair peptide baseline. The framework operates under AMA Code 1.1.5 with foundational safety markers and pharmacy verification.
PSI's reading: compounded tissue repair peptide baseline bloodwork is anchored in AMA Code of Medical Ethics 1.1.5 framework. The two foundational markers (CMP and CBC) provide safety baseline. Additional markers may apply per clinical context including inflammation markers (CRP, ESR) for inflammatory indications, hormone panel for hormonal context, and lipid panel for general cardiovascular baseline. The 503A or 503B pharmacy verification framework applies including state license or FDA registration, PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing. The four-stage monitoring cadence applies with conservative intervals given the limited human evidence base. AMA Code 1.1.5 documentation includes risk-benefit assessment, FDA-approved alternatives considered (physical therapy, NSAIDs, corticosteroid injections, PRP, surgical intervention as applicable), monitoring requirements, and patient understanding. Specialty coordination with orthopedics, sports medicine, or physical medicine and rehabilitation strengthens the framework. The PSI physician directory provides verified physicians.
How to Approach Your Decision
- For compounded BPC-157 therapy, expect baseline CMP and CBC plus AMA Code 1.1.5 documentation.
- For compounded TB-500 therapy, expect the same baseline plus WADA prohibition awareness if subject to anti-doping testing.
- For compounded pathways, verify 503A state pharmacy license or 503B FDA registration documentation.
- Expect PCAB accreditation status plus USP Chapter 797 and 800 compliance verification.
- Expect third-party purity and potency testing including USP 71 sterility and HPLC potency analysis.
- For tissue repair indications, expect FDA-approved alternative consideration including PT, NSAIDs, PRP.
- For specialty coordination, expect orthopedics, sports medicine, or PM and R input as clinically indicated.
- For monitoring, expect four-stage cadence with CMP and CBC re-check at month 3 stabilization and month 6.
Limitations and Caveats
- The evidence base for BPC-157 and TB-500 efficacy is primarily preclinical. Human trial data is limited and the available human studies have been small with short follow-up.
- The compounded preparations operate outside FDA pre-market approval. Neither compound has FDA-approved product status. The framework operates under the FDA Compounding Quality Act of 2013.
- AMA Code of Medical Ethics 1.1.5 documentation is mandatory. The documentation includes risk-benefit assessment, alternatives considered, monitoring requirements, and patient understanding.
- FDA-approved alternatives apply for tissue repair indications. Physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma, and surgical intervention depending on the specific condition.
- TB-500 is on the WADA prohibited list. Athletes subject to anti-doping testing should be aware of the prohibition status before any compounded TB-500 therapy decision.
- Physician pharmacy verification is required for 503A or 503B pathways. Verification includes state license or FDA registration, PCAB accreditation, USP compliance, and third-party testing.
- Long-term safety data is limited. Conservative monitoring intervals strengthen the safety framework given the limited human evidence base.
- Specialty coordination strengthens the framework. Complex tissue repair indications benefit from orthopedics, sports medicine, or PM and R input.
What's Marketed vs What's Studied
7 common claims, corrected.
“Compounded BPC-157 and TB-500 are FDA-approved drugs.”
Neither BPC-157 nor TB-500 has FDA-approved product status. Both compounds are available only through compounded pathways operating outside FDA pre-market approval per the FDA Compounding Quality Act of 2013. AMA Code of Medical Ethics 1.1.5 framework applies.
“Tissue repair peptides do not require baseline bloodwork.”
Compounded tissue repair peptide therapy requires baseline CMP and CBC for safety assessment. AMA Code of Medical Ethics 1.1.5 framework requires documented baseline laboratory assessment as part of informed consent for off-label and compounded prescribing.
“BPC-157 has been proven effective in human trials.”
The evidence base for BPC-157 is primarily preclinical with limited human trial data. The available human studies have been small with short follow-up. AMA Code 1.1.5 framework requires documented patient understanding of evidence base limitations.
“TB-500 is safe for athletes during competition.”
TB-500 is on the World Anti-Doping Agency prohibited list as a non-specified substance under category S2 peptide hormones, growth factors, and related substances. Athletes subject to anti-doping testing should be aware of the prohibition status.
“Compounded peptides do not require pharmacy verification.”
Compounded BPC-157 and TB-500 prescribing requires physician verification of 503A state pharmacy or 503B FDA-registered outsourcing facility. Verification includes PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing practices.
“Self-sourcing BPC-157 or TB-500 from research chemical sites is the same as physician-prescribed compounded preparations.”
Research chemical sources operate outside the FDA Compounding Quality Act of 2013 framework. The preparations lack 503A or 503B pharmacy oversight, PCAB accreditation, USP compliance, and third-party testing. Quality, purity, and safety are not assured.
“FDA-approved alternatives do not apply to compounded peptide prescribing.”
AMA Code of Medical Ethics 1.1.5 framework requires consideration of FDA-approved alternatives before compounded peptide prescribing. For tissue repair indications, alternatives include physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma, and surgical intervention depending on the specific condition.
Common Questions
What baseline bloodwork is required before BPC-157 therapy?
Baseline panel includes comprehensive metabolic panel (CMP) for kidney and liver function plus complete blood count (CBC) for hematologic baseline. Additional markers may apply per clinical context including inflammation markers for inflammatory indications. AMA Code of Medical Ethics 1.1.5 documentation is required. Physician pharmacy verification of 503A or 503B applies.
What baseline bloodwork is required before TB-500 therapy?
Baseline panel matches BPC-157: CMP and CBC for foundational safety baseline. AMA Code 1.1.5 documentation is required including the WADA prohibition awareness for athletes subject to anti-doping testing. Physician pharmacy verification of 503A or 503B applies. Specialty coordination strengthens the framework.
Is BPC-157 FDA-approved?
No. BPC-157 has no FDA-approved product status. The compound is available only through compounded pathways operating outside FDA pre-market approval per the FDA Compounding Quality Act of 2013. AMA Code of Medical Ethics 1.1.5 framework applies to all compounded BPC-157 prescribing.
Is TB-500 FDA-approved?
No. TB-500 has no FDA-approved product status. The compound is available only through compounded pathways. TB-500 is also on the World Anti-Doping Agency prohibited list as a non-specified substance. Athletes subject to anti-doping testing should be aware of the prohibition status before any therapy decision.
What is the evidence base for BPC-157?
The evidence base for BPC-157 is primarily preclinical with limited human trial data. Preclinical animal studies have examined tissue repair indications including tendon, ligament, muscle, gastric mucosa, and inflammatory bowel disease contexts. Human studies have been small with short follow-up. AMA Code 1.1.5 framework requires documented patient understanding.
What is the evidence base for TB-500?
The evidence base for TB-500 is primarily preclinical with limited human trial data. Preclinical animal studies have examined tissue repair indications including cardiac, neural, and musculoskeletal contexts. The full thymosin beta-4 molecule has been studied more extensively but TB-500 specifically as the 17 amino acid fragment has limited human data.
What FDA-approved alternatives apply to tissue repair indications?
FDA-approved alternatives for tissue repair indications include physical therapy as first-line for most musculoskeletal indications, NSAIDs (ibuprofen, naproxen) for inflammatory pain, corticosteroid injections for joint and tendon indications, platelet-rich plasma injection therapy, prolotherapy, and surgical intervention for indications meeting surgical criteria. AMA Code 1.1.5 framework requires documented consideration.
Why is AMA Code 1.1.5 documentation required for compounded BPC-157 and TB-500?
AMA Code of Medical Ethics 1.1.5 governs off-label and investigational use of pharmaceuticals. Compounded peptide prescribing falls under this framework given the compounded preparations operate outside FDA pre-market approval. The documentation includes risk-benefit assessment, alternatives considered, monitoring requirements, and patient understanding.
How do I verify the 503A or 503B pharmacy for my compounded peptide?
503A state license verification is through the state pharmacy board portal for the state where the pharmacy operates. 503B FDA registration verification is through the FDA Drug Establishment Registration database. PCAB accreditation status is verified through the PCAB website. Patients should request the specific pharmacy name from their prescribing physician.
What is USP Chapter 797 and 800 compliance?
USP Chapter 797 sterile compounding compliance addresses sterile preparation protocols including aseptic technique, environmental monitoring, beyond-use dating, and personnel qualification. USP Chapter 800 hazardous drug handling compliance addresses worker safety and patient exposure protocols. Both standards apply to compounded peptide preparations.
What third-party testing should compounded BPC-157 or TB-500 have?
Third-party purity and potency testing typically includes USP 71 sterility testing (validating sterile preparation status), USP 85 bacterial endotoxin testing (validating freedom from endotoxin contamination), and HPLC potency analysis (validating active ingredient concentration). Patients can request testing documentation from the prescribing physician.
How often is bloodwork repeated during compounded peptide therapy?
Bloodwork follows a four-stage cadence: baseline at week 0, early follow-up at week 4 to 8, stabilization at month 3, and maintenance at month 6 with annual continuation. Given the limited human evidence base for BPC-157 and TB-500, conservative monitoring intervals strengthen the safety framework.
Can my primary care physician order compounded peptide baseline bloodwork?
Primary care can order baseline CMP and CBC for compounded peptide therapy. AMA Code 1.1.5 framework applies including the off-label and investigational use documentation. For complex tissue repair indications, specialty coordination with orthopedics, sports medicine, or physical medicine and rehabilitation strengthens the framework.
Will my insurance cover compounded BPC-157 or TB-500?
Insurance coverage for compounded peptide preparations is typically limited or absent. The preparations are typically billed cash. Insurance coverage for the baseline bloodwork (CMP, CBC) is generally available under standard laboratory coverage. Insurance coverage for AMA Code 1.1.5 documented visits follows standard office visit coverage.
What if I am an athlete subject to anti-doping testing?
TB-500 is on the World Anti-Doping Agency prohibited list as a non-specified substance under category S2 peptide hormones, growth factors, and related substances. BPC-157 is currently a monitored substance but not on the WADA Prohibited List as of 2024. Athletes should consult their sport governing body for specific guidance.
Can I get compounded peptide bloodwork through telehealth?
Yes. Telehealth compounded peptide bloodwork orders go through external laboratory networks like Quest Diagnostics, LabCorp, or local laboratory networks. The patient visits the laboratory for sample collection. AMA Code 1.1.5 documentation and 503A or 503B pharmacy verification can be coordinated through telehealth visits.
What happens if BPC-157 or TB-500 does not produce the expected response?
Inadequate response to compounded BPC-157 or TB-500 requires clinical re-evaluation. The framework includes re-assessment of the tissue repair indication, alternative FDA-approved therapy consideration, specialty coordination with orthopedics or sports medicine, and potentially surgical evaluation depending on the specific condition. AMA Code 1.1.5 framework supports the decision.
Where can I find a physician for compounded tissue repair peptide therapy?
The PSI physician directory provides verified physicians across major US cities including peptide therapy experience verification, state medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice verification. The directory covers orthopedics, sports medicine, and physical medicine and rehabilitation specialists.
Evidence Ranking
Rank 1
AMA Code of Medical Ethics 1.1.5 documentation
Strongest framework anchoring: mandatory documentation for all compounded peptide prescribing per AMA Code of Medical Ethics framework.
Rank 2
503A or 503B pharmacy verification
Strong framework anchoring: FDA Compounding Quality Act of 2013 requires pharmacy verification including state license or FDA registration.
Rank 3
Comprehensive metabolic panel (CMP)
Strong evidence anchoring: foundational safety baseline for compounded peptide therapy covering kidney, liver, and electrolyte status.
Rank 4
Complete blood count (CBC)
Strong evidence anchoring: foundational hematologic baseline plus occult disease screening for compounded peptide therapy.
Rank 5
USP Chapter 797 and 800 compliance verification
Strong framework anchoring: sterile compounding and hazardous drug handling standards apply to all compounded peptide preparations.
Rank 6
Third-party purity and potency testing
Moderate evidence anchoring: USP 71 sterility, USP 85 endotoxin, and HPLC potency testing support compounded preparation quality.
Sourcing Checklist
Order baseline bloodwork through prescribing physician with documented clinical interpretation.
Self-ordered direct-to-consumer bloodwork is not a substitute for physician-ordered baseline. AMA Code 1.1.5 informed consent requires physician clinical interpretation.
Confirm AMA Code of Medical Ethics 1.1.5 documentation before initiation.
The documentation includes risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding.
Verify 503A state pharmacy license or 503B FDA registration before any compounded prescription fill.
503A verification is through state pharmacy board portal. 503B verification is through FDA Drug Establishment Registration database.
Confirm PCAB accreditation status of the compounding pharmacy.
PCAB (Pharmacy Compounding Accreditation Board) accreditation is verified through the PCAB website and provides quality assurance verification.
Confirm USP Chapter 797 sterile compounding and USP Chapter 800 hazardous drug handling compliance.
USP 797 addresses aseptic technique, environmental monitoring, beyond-use dating. USP 800 addresses worker safety and patient exposure protocols.
Request third-party purity and potency testing documentation.
Testing typically includes USP 71 sterility testing, USP 85 bacterial endotoxin testing, and HPLC potency analysis for active ingredient concentration verification.
Confirm FDA-approved alternatives have been considered per AMA Code 1.1.5.
For tissue repair indications, alternatives include physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma, and surgical intervention.
For TB-500 specifically, confirm awareness of WADA prohibition for athletes subject to anti-doping testing.
TB-500 is on the WADA Prohibited List as non-specified substance under category S2 peptide hormones, growth factors, and related substances.
Expect four-stage monitoring cadence with conservative intervals given limited human evidence base.
Baseline week 0, early follow-up week 4-8, stabilization month 3, maintenance month 6 plus annual continuation. CMP and CBC re-check supports safety framework.
Regulatory Context
The regulatory framework governing compounded tissue repair peptide therapy evolves continuously. The FDA Compounding Quality Act enforcement landscape evolves with state pharmacy board oversight cycles and 503B outsourcing facility inspection cadences. FDA scrutiny on compounded BPC-157 and TB-500 may evolve based on adverse event reports through FDA MedWatch and post-marketing surveillance. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks remain foundational with periodic refinements. USP Chapter 797 and 800 standards update periodically. World Anti-Doping Agency Prohibited List updates annually with TB-500 currently on the prohibited list. PSI tracks regulatory changes and updates this page per the Editorial Standards review cadence.
Comparison
| Compound | Regulatory Status | Baseline Markers | Key Considerations |
|---|---|---|---|
| BPC-157 (compounded) | No FDA-approved product. 503A or 503B compounded. | CMP + CBC + AMA 1.1.5 docs | Evidence base primarily preclinical. Limited human trial data. |
| TB-500 (compounded) | No FDA-approved product. 503A or 503B compounded. | CMP + CBC + AMA 1.1.5 docs + WADA awareness | WADA prohibited. Limited human trial data. Synthetic thymosin beta-4 fragment. |
| Physical therapy (FDA-approved alternative) | Standard medical practice | Not applicable (no peptide) | First-line for most musculoskeletal tissue repair indications |
| NSAIDs (FDA-approved alternative) | Over-the-counter and prescription | Periodic CMP for liver/kidney monitoring | Ibuprofen, naproxen for inflammatory pain. Watch GI and renal toxicity. |
| Corticosteroid injections (FDA-approved alternative) | Standard medical practice | Glucose for diabetics | Joint and soft tissue indications. Caution for tendon insertions. |
| Platelet-rich plasma (PRP) injection therapy | FDA-cleared device-based preparations | CBC baseline for autologous preparation | Autologous blood-derived. Insurance coverage varies by indication. |
| AMA Code 1.1.5 framework | Mandatory for compounded peptide prescribing | Documentation only | Risk-benefit, alternatives, monitoring, patient understanding |
| 503A or 503B pharmacy verification | FDA Compounding Quality Act 2013 | Documentation only | State license or FDA registration, PCAB, USP 797 and 800, third-party testing |
Who This Applies To
- · Adult considering compounded BPC-157 for tissue repair indication under AMA Code 1.1.5 framework.
- · Adult considering compounded TB-500 for tissue repair indication under AMA Code 1.1.5 framework.
- · Athlete subject to anti-doping testing evaluating TB-500 prohibition status.
- · Adult with tendon or ligament injury comparing FDA-approved alternatives to compounded options.
- · Adult considering tissue repair peptide therapy after physical therapy and NSAID failure.
- · Adult preparing for 503A or 503B pharmacy verification documentation.
- · Adult evaluating evidence base limitations for compounded tissue repair peptides.
- · Patient considering specialty coordination with orthopedics or sports medicine.
- · Patient considering telehealth compounded peptide consultation with external lab bloodwork.
- · Patient planning four-stage monitoring cadence for compounded tissue repair therapy.
Verdict
Compounded tissue repair peptide therapy with BPC-157 and TB-500 requires foundational safety baseline (CMP and CBC) plus AMA Code of Medical Ethics 1.1.5 documentation. The framework operates under the FDA Compounding Quality Act of 2013. Neither compound has FDA-approved product status. The evidence base is primarily preclinical with limited human trial data. Physician verification of 503A state pharmacy or 503B FDA registration is required. PCAB accreditation plus USP Chapter 797 and 800 compliance applies. TB-500 is on the WADA Prohibited List for athletes. FDA-approved alternatives apply per AMA Code 1.1.5 including physical therapy, NSAIDs, corticosteroid injections, platelet-rich plasma, and surgical intervention. Monitoring follows a four-stage cadence.
In Plain Terms
Tissue repair peptides like BPC-157 and TB-500 are compounded drugs. They are not FDA-approved. Before starting, your doctor orders CMP (kidney and liver) and CBC (blood count) for safety. Your doctor also documents the risk-benefit and considers FDA-approved alternatives like physical therapy and NSAIDs. The pharmacy must be a 503A or 503B compounder with proper licensing. TB-500 is banned for athletes under WADA rules. The evidence base is mostly from animal studies with limited human data.
BPC-157 and TB-500 are compounded peptides for tissue repair. They are not FDA-approved. Your doctor orders basic safety labs (CMP and CBC) before starting. Your doctor also documents the risk-benefit per AMA rules. The pharmacy must be properly licensed. TB-500 is banned for competitive athletes. The evidence is mostly from animal studies. FDA-approved options like physical therapy should be considered first.
For compounded tissue repair peptide therapy, physician selection through state medical board license verification, ABMS board certification (orthopedics, sports medicine, or physical medicine and rehabilitation preferred for tissue repair indications), and AMA Code 1.1.5 framework adherence is the legal and clinical gate. PSI maintains a vetted directory of practitioners ordering comprehensive baseline bloodwork and verifying 503A or 503B pharmacy quality assurance.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Related Conditions
Related Education
Featured Compounds
Common Contexts
- · Adult considering compounded BPC-157 for tissue repair after physical therapy and NSAID consideration
- · Adult considering compounded TB-500 for tissue repair under AMA Code 1.1.5 documentation framework
- · Athlete subject to anti-doping testing evaluating TB-500 WADA prohibition status implications
- · Adult with tendon or ligament injury comparing FDA-approved alternatives to compounded peptide options
- · Adult preparing for 503A state pharmacy or 503B FDA-registered outsourcing facility verification
- · Adult evaluating evidence base limitations including primarily preclinical animal studies
- · Patient seeking specialty coordination with orthopedics, sports medicine, or physical medicine and rehabilitation
- · Patient considering telehealth compounded peptide consultation with external laboratory baseline bloodwork
- · Patient planning four-stage monitoring cadence given limited human evidence base for safety surveillance
- · Patient comparing compounded BPC-157 versus TB-500 pathways including WADA prohibition status differences
Important Context
This page is educational and does not constitute medical advice. The information presented reflects AMA Code of Medical Ethics 1.1.5 and 2.1.1 for off-label and compounded prescribing, the FDA Compounding Quality Act of 2013 (503A and 503B pharmacy framework), USP Chapter 797 sterile compounding standards, USP Chapter 800 hazardous drug handling standards, World Anti-Doping Agency Prohibited List 2024 (relevant for TB-500 athlete contexts), and FDA MedWatch adverse event reporting framework as referenced. BPC-157 and TB-500 have no FDA-approved product status.
Your physician will order the specific baseline panel appropriate to the compounded tissue repair peptide, your tissue repair indication, your clinical context including prior interventions tried, and your prior bloodwork records. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination strengthens complex decisions across primary care, orthopedics, sports medicine, physical medicine and rehabilitation, and other relevant specialties.
Self-ordering of bloodwork through direct-to-consumer laboratory services is not a substitute for physician-ordered baseline assessment with documented clinical interpretation. Quality clinical practice orders bloodwork in the context of the indication-specific evaluation and reviews results with the patient as part of AMA Code 1.1.5 informed consent documentation. Self-sourcing of compounded peptide preparations outside the physician-prescribing pathway operates outside the validated clinical practice framework.
Educational content only. Discuss with your physician before pursuing compounded tissue repair peptide therapy. BPC-157 and TB-500 have no FDA-approved product status. AMA Code 1.1.5 framework applies including documented risk-benefit assessment, alternatives considered, monitoring requirements, and patient understanding. TB-500 is on the WADA prohibited list for athletes subject to anti-doping testing.
Sources and Citations
- [1] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
- [2] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
- [3] FDA Compounding Quality Act of 2013: 503A pharmacy and 503B outsourcing facility framework · US Food and Drug Administration · 2013 · Source
- [4] FDA Guidance: Section 503A Pharmacy Compounding Under the Federal Food, Drug, and Cosmetic Act · US Food and Drug Administration · 2024 · Source
- [5] FDA Guidance: Section 503B Outsourcing Facilities · US Food and Drug Administration · 2024 · Source
- [6] USP General Chapter 797 Pharmaceutical Compounding - Sterile Preparations · United States Pharmacopeia · 2024 · Source
- [7] USP General Chapter 800 Hazardous Drugs - Handling in Healthcare Settings · United States Pharmacopeia · 2024 · Source
- [8] USP General Chapter 71 Sterility Tests · United States Pharmacopeia · 2024
- [9] USP General Chapter 85 Bacterial Endotoxins Test · United States Pharmacopeia · 2024
- [10] Pharmacy Compounding Accreditation Board (PCAB) Standards · Accreditation Commission for Health Care · 2024 · Source
- [11] World Anti-Doping Agency (WADA) Prohibited List 2024 - Category S2 Peptide Hormones, Growth Factors, and Related Substances · World Anti-Doping Agency · 2024 · Source
- [12] Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs - Counteraction by Stable Gastric Pentadecapeptide BPC 157 (BPC-157 preclinical review) · Current Pharmaceutical Design · 2010 · PubMed
- [13] Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues (thymosin beta-4 review) · Trends in Molecular Medicine · 2005 · DOI
- [14] FDA Alert: Concerns Regarding Compounded Peptides Including BPC-157 (FDA post-market surveillance) · US Food and Drug Administration · 2024 · Source
- [15] FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program · US Food and Drug Administration · 2024 · Source
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.